Next‐Generation Vaccines: Nanoparticle‐Mediated DNA and mRNA Delivery

• Published in: Advanced healthcare materials Vol. 10; no. 8; pp. e2001812 - n/a
• Main Authors: Ho, William, Gao, Mingzhu, Li, Fengqiao, Li, Zhongyu, Zhang, Xue‐Qing, Xu, Xiaoyang
• Format: Journal Article
• Language: English
• Published: Germany Wiley Subscription Services, Inc 01.04.2021; John Wiley and Sons Inc
• Subjects: Acids; Adaptability; Antigens; Clinical trials; COVID-19; Deoxyribonucleic acid; DNA; DNA vaccines; Gene sequencing; Humans; Humoral immunity; Immune response; Immune system; Immunization; mRNA; mRNA vaccines; Nanoparticles; nucleic acid; Nucleic acids; Nucleotide sequence; Pandemics; Review; RNA, Messenger; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; Stimulation; vaccine delivery; Vaccines; Viral diseases; vaccine delivery; mRNA; nanoparticles; nucleic acid; vaccines; DNA
• ISSN: 2192-2640; 2192-2659; 2192-2659
• DOI: 10.1002/adhm.202001812

Nucleic acid vaccines are a method of immunization aiming to elicit immune responses akin to live attenuated vaccines. In this method, DNA or messenger RNA (mRNA) sequences are delivered to the body to generate proteins, which mimic disease antigens to stimulate the immune response. Advantages of nucleic acid vaccines include stimulation of both cell‐mediated and humoral immunity, ease of design, rapid adaptability to changing pathogen strains, and customizable multiantigen vaccines. To combat the SARS‐CoV‐2 pandemic, and many other diseases, nucleic acid vaccines appear to be a promising method. However, aid is needed in delivering the fragile DNA/mRNA payload. Many delivery strategies have been developed to elicit effective immune stimulation, yet no nucleic acid vaccine has been FDA‐approved for human use. Nanoparticles (NPs) are one of the top candidates to mediate successful DNA/mRNA vaccine delivery due to their unique properties, including unlimited possibilities for formulations, protective capacity, simultaneous loading, and delivery potential of multiple DNA/mRNA vaccines. This review will summarize the many varieties of novel NP formulations for DNA and mRNA vaccine delivery as well as give the reader a brief synopsis of NP vaccine clinical trials. Finally, the future perspectives and challenges for NP‐mediated nucleic acid vaccines will be explored. Nucleic acid vaccines can be loaded onto a nanoparticle platform for delivery. Once administered, the vaccine is taken up by either local cells or antigen presenting cells. The payload is released and processed by the cell machinery to create the coded antigen, further processed for display to other immune cells, and subsequent immune activation leads to humoral and cell‐mediated immunity.